PFE : Analysis & Opinions

  • Showing 1-100 of 200 items
  • 1
  • 2
  • >>
  1. Warning: 5 Popular Stocks You Need To Sell Now

    February 11, 2015
    These are five of the most widely owned stocks in the market. You have, without a doubt, heard of them, and it's very possible ...
  2. Warning: 5 Popular Stocks You Need to Consider Selling Now

    February 11, 2015
    These are five of the most widely owned stocks in the market. You have, without a doubt, heard of them, and it's very possible ...
  3. Stock Market News for January 28, 2015 - Market News

    January 28, 2015
    Disappointing earnings results dragged down benchmarks on Tuesday to their biggest one-day losses in three weeks
  4. Pfizer Inc. (PFE): New Analyst Report from Zacks Equity Research ...

    January 28, 2015
    Pfizer's fourth quarter 2014 earnings of $0.54 per share were a penny above the Zacks Consensus Estimate but 4% below the ...
  5. Bristol-Myers Beats on Q4 Earnings, 2015 View Disappoints - Analyst ...

    January 27, 2015
    Bristol-Myers Squibb Company reported fourth-quarter 2014 earnings of 46 cents per share.
  6. Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst ...

    January 27, 2015
    Pfizer's (PFE) 2015 guidance disappointed with results expected to be hit by genericization as well as unfavorable currency ...
  7. Pfizer's Prevenar 13 Wins CHMP Backing for Expanded Use - Analyst ...

    January 26, 2015
    Pfizer's (PFE) Prevenar 13 is a step closer to EU approval with the CHMP giving a favorable opinion for the prevention of ...
  8. Will Novartis' (NVS) Earnings Disappoint Expectations in Q4? ...

    January 23, 2015
    Switzerland-based Novartis AG (NVS), one of the leading players in the healthcare solutions, will be reporting its fourth-quarter ...
  9. Will Oncology Products Drive Bristol-Myers (BMY) Earnings? - ...

    January 23, 2015
    Bristol-Myers Squibb Company (BMY) is scheduled to report its fourth-quarter 2014 results on Jan 27, before the opening bell.
  10. Will Pfizer (PFE) Beat Q4 Earnings Despite Generics? - Analyst ...

    January 23, 2015
    Will Pfizer's (PFE) earnings streak continue despite the entry of Celebrex generics in late December?
  11. How the S&P 500 and Russell 2000 Indexes Differ

    January 22, 2015
    The S&P 500 and Russell 2000 are used as benchmarks for broader segments of the U.S. stock market. Each index has its own ...
  12. Immunomedics Reports Data on Oncology Candidate - Analyst Blog

    January 21, 2015
    Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan ...
  13. Will Pharmaceutical Segment Drive J&J Q4 Earnings Again? - Analyst ...

    January 19, 2015
    Will pharma product sales and newly launched products continue to be the driving force in the fourth quarter?
  14. Agilent Arm/Cell Signaling Tie for Companion Diagnostics - Analyst ...

    January 15, 2015
    Agilent Technologies (A) subsidiary, recently entered into a strategic partnership with Cell Signaling Technology to develop ...
  15. ARIAD Reveals 2015 Strategic Objectives, Updates on Pipeline ...

    January 14, 2015
    ARIAD Pharmaceuticals, Inc. (ARIA) announced its key strategic objectives for 2015 and its aim to increase R&D and expand ...
  16. Argos Therapeutics Falls on Disappointing Phase IIb HIV Data ...

    January 12, 2015
    Argos Therapeutics Inc.'s (ARGS) AGS-004 failed to meet the primary endpoint in a phase IIb study for the treatment of patients ...
  17. Dow 30 Stock Roundup: Pfizer Acquires Redvax, Microsoft Launches ...

    January 9, 2015
    The Dow started the week on a poor note before recovering considerably.
  18. 3 Pharma Stocks That Soared Past Pfizer in 2014 - Analyst Blog

    January 9, 2015
    Like many of its pharma counterparts, Pfizer's (PFE) top-line remained under pressure due to generic competition for several ...
  19. Pfizer Boosts Vaccine Pipeline with Redvax Acquisition - Analyst ...

    January 7, 2015
    Pfizer's (PFE) acquisition of Redvax makes the company one of the leaders in CMV research and development.
  20. Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst ...

    January 6, 2015
    Immunomedics, Inc.'s (IMMU) sacituzumab govitecan has received fast track status from the FDA for triple-negative breast ...
  21. 5 Dogs of the Dow Stocks for 2015 - Analyst Blog

    December 31, 2014
    The Dow has had an extremely good year, gaining 8.5% to date.
  22. Athersys Finishes Enrollment for MultiStem Cell Therapy Trial ...

    December 30, 2014
    Athersys (ATHX) announced the completion of patient enrolment process for a phase II study on its MultiStem cell therapy.
  23. Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst ...

    December 18, 2014
    Pfizer (PFE) has moved its experimental Duchenne muscular dystrophy treatment into a phase II study.
  24. Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst ...

    December 18, 2014
    Shares of Halozyme (HALO) jumped after announcing a worldwide collaboration and license agreement with Johnson & Johnson ...
  25. Jacobs Drives Organic Growth on Award-Winning Contract - Analyst ...

    December 17, 2014
    Jacobs Engineering Group Inc. (JEC) recently received the Facility of the Year Award (FOYA) for successfully delivering the ...
  26. OncoGenex's Pancreatic Cancer Study Fully Enrolled - Analyst ...

    December 17, 2014
    OncoGenex Pharmaceuticals, Inc. (OGXI) has completed enrolling patients in its phase II Rainier study on apatorsen for previously ...
  27. Baxter to Vend Vero Cell Vaccine Platform to Nanotherapeutics ...

    December 16, 2014
    Baxter International Inc (BAX) is set to divest its Vero cell technology and related assets to Nanotherapeutics, Inc for ...
  28. The Best Way Into Big Pharma? See This ETF (IHE)

    November 21, 2014
    Pharma investing isn't for everyone, but sector-specific ETFs, such as the iShares Dow Jones U.S. Pharmaceuticals ETF (IHE), ...
  29. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  30. Get Ready for Shift in Fed Policy - Ahead of Wall Street

    October 28, 2014
    The Fed genuinely wants to get out of the QE business and start the monetary policy 'normalization' process.
  31. The Biggest Mergers & Acquisitions In The U.S.

    October 23, 2014
    M&A is a daily part of the American business world. They're based on the principle that "One plus one equals three," i.e. ...
  32. Profit From The Largest Generation In History: 2 Companies Boomers ...

    October 8, 2014
  33. How Merck Found Its Way Into Millions Of Medicine Cabinets

    September 15, 2014
    With over $40 billion in revenue from pharmaceutical sales, there's a good chance that you'll be very grateful for one of ...
  34. MedTech Defies Sequestration, M&As Steal the Show - Industry ...

    August 26, 2014
    MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
  35. An Investing Legend Predicts A Major M&A Boom -- Here's How To ...

    August 7, 2014
    Some high-profile buyout deals have been falling apart lately. For instance, the third largest U.S. wireless carrier Sprint ...
  36. Why There's Far More To Pfizer Than Viagra

    July 30, 2014
    Pfizer, Inc. is one of the world's largest and most profitable pharmaceutical companies, and not just because of that little ...
  37. Q3 Estimates Beginning to Slip - Ahead of Wall Street

    July 29, 2014
    Lower revisions to the magnitude of Q3 estimates will still be a net positive -- we will see how this trend unfolds.
  38. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  39. Interested In Healthcare Stocks? Look At This ETF

    July 3, 2014
    Healthcare companies seem to be poised to make a move higher over the months ahead. Here's an ETF that should be helpful ...
  40. Invest In Share Buybacks With This ETF

    June 13, 2014
    In most cases, when a company buys its own shares on the open market it's a signal to investors that they're undervalued. ...
  41. #PreMarket Primer: Tuesday, May 27: Hope Rises In Ukraine Despite ...

    May 27, 2014
    Following the election of billionaire Petro Poroshenko as President of Ukraine, diplomatic tensions seemed to be easing ...
  42. Global Markets Indicate Weakness - Ahead of Wall Street

    May 19, 2014
    Pre-open sentiment is pointing to a weak start for U.S. stocks, with soft overnight trading action across global markets.
  43. #PreMarket Primer: Monday, May 19: DirecTV Rises On Offer From ...

    May 19, 2014
    AT&T Inc. announced a deal to acquire DirecTV for $49 billion over the weekend, as the firm attempts to adapt to a quickly ...
  44. What Are The Best Bets In Biotech?

    May 2, 2014
    The NASDAQ Biotechnology Index is off nearly 20% as its components busy themselves with hostile bids and frenzied buying ...
  45. A Big Week for Economic & Earnings Data - Ahead of Wall Street

    April 28, 2014
    The week is packed with economic and Q1 earnings reports.
  46. How Johnson & Johnson Became A Household Name

    April 21, 2014
    New Brunswick, N.J.-based Johnson & Johnson (NYSE:JNJ) is probably most famous as the parent company of multiple household ...
  47. Hedge Funds Love These 3 Pharma Stocks

    April 14, 2014
    In 2012, the star performer among sectors was the financial sector. In 2013, it was consumer discretionary stocks. For 2 ...
  48. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  49. These Companies Know The Future Before It Happens

    February 13, 2014
    Wouldn't it be great to have a crystal ball to see into the future?You could know when the next market crash will be, ...
  50. Buybacks Instead of Capital Investment - Ahead of Wall Street

    January 28, 2014
    Hard to make sense of the fact that companies would consider it prudent to invest in their own sharesinstead of their businesses.
  51. Capital Spending vs. Buybacks - Ahead of Wall Street

    December 24, 2013
    If the Durable Goods report is a sign of things to come, then it would be a material improvement in the economic outlook.
  52. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  53. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  54. It's No Accident That Drugs Are Expensive

    August 30, 2013
    Branded drugs are expensive in large part because it's expensive and risky to develop them
  55. Better Margins Can't Hide Merck's Growth Challenges

    July 30, 2013
    Merck's near-term growth is looking weak, but margin improvements and an underestimated pipeline could offer upside.
  56. Pfizer Looking A Little Tired

    July 30, 2013
    Pfizer gets a boost from better margins, but the growth outlook is pretty feeble.
  57. 8 Stages Of New Drug Development

    July 29, 2013
    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these ...
  58. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  59. Weak Earnings Growth Outside Finance - Earnings Trends

    July 25, 2013
    Weak Earnings Growth Outside Finance - Earnings Trends
  60. Drugs Driving JNJ, With Slow Progress In Devices And Consumer

    July 17, 2013
    JNJ is getting great performance out of its drug business, but the remainder still lags.
  61. FDA Accepts Pfizer sNDA - Analyst Blog

    June 26, 2013
    The FDA's decision regarding the Xeljanz label expansion should be out by Feb 2014.
  62. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  63. Pfizer Gives Up Stake in Zoetis - Analyst Blog

    June 25, 2013
    Pfizer lowered its outlook for 2013 to reflect the impact of the divestment of the remaining stake in Zoetis.
  64. ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...

    June 24, 2013
    Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
  65. Big Pharma Faces 'Pay For Delay' Lawsuits

    June 21, 2013
    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of ...
  66. Ariad's Iclusig in GIST Phase II Study - Analyst Blog

    June 18, 2013
    The study will evaluate Iclusig's efficacy and safety in patients who have failed at least one tyrosine kinase inhibitor ...
  67. Make Money From Spinoffs

    June 4, 2013
    According to Barrons, 15 spinoffs have taken place in 2013 through the end of May, 50% more than last year. It seems all ...
  68. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  69. Coty Readies IPO

    May 28, 2013
    Fragrance maker Coty filed a registration statement amendment May 28 that sees it raising as much as $1.2 billion from its ...
  70. After A Big Rally, Pfizer Might Need Some Rest

    May 21, 2013
    A big rally has brought Pfizer back to fair value.
  71. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  72. The “Healthy” Play In Contract Research Organizations

    April 17, 2013
    The pharmaceutical industry is under pressure to do more with less. That means it will be farming out many of is mundane ...
  73. Agilent Misses, Guidance Disappoints - Analyst Blog

    February 15, 2013
    Agilent Technologies' A) fiscal first quarter earnings per share of 63 cents missed the Zacks Consensus Estimate by 4 cents, ...
  74. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  75. Pfizer Readies Zoetis For Market

    January 23, 2013
    Pfizer filed further details about its tentative spin-off of Zoetis, its animal health business.
  76. Data on Novartis' Afinitor - Analyst Blog

    January 14, 2013
    As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size ...
  77. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  78. A Look Back At The Year In Pharmaceuticals

    December 28, 2012
    Pharmaceuticals have had a decidedly mixed year in 2012, largely on the basis of the revenue growth outlook.
  79. BASF's Deal For Pronova Shows The Importance Of Good Nutrition

    November 23, 2012
    BASF ties up another high-grade fish oil company in Pronovna, adding to the recent rise in popularity for the fish oil space.
  80. Pfizer's Lyrica Scores in Study - Analyst Blog

    November 21, 2012
    Pfizer Inc. (PFE) recently announced positive top-line data on its once-daily formulation of Lyrica (pregabalin). Results ...
  81. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  82. Bayer Buys Schiff Nutrition International: Winners All Around

    November 7, 2012
    Bayer announced November 2 that it's buying Schiff for $1.2 billion to bulk up its consumer business.
  83. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  84. Pfizer's Third Quarter Earnings Report

    November 1, 2012
    Pfizer (NYSE:PFE) announced its results for the most recent quarter on November 1, 2012. Pfizer is a global pharmaceutical ...
  85. Pfizer Third Quarter Earnings Preview

    October 25, 2012
    When Pfizer (NYSE:PFE) releases its third quarter earnings on Tuesday, October 30, 2012, analysts are expecting a 16.1% drop ...
  86. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  87. Pfizer Is Near a Key Resistance Area

    September 27, 2012
    New York, September 27th ( - Shares of Pfizer, Inc. (NYSE:PFE) are trading very close to calculated resistance ...
  88. Pfizer Looks To Spin Off Animal Health Unit

    August 15, 2012
    Pfizer has filed plans to sell up to 20% of its animal-health unit in the first half of 2013 to focus on human pharmaceuticals. ...
  89. The Week Ahead In Healthcare

    August 13, 2012
    The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit, likely in part because Johnson & ...
  90. Huntington Launches Sector Rotation ETF (HUSE)

    July 30, 2012
    Huntington, fresh off its initial foray into the ETF industry in June, has doubled the size of its lineup with the launch ...
  91. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  92. 4 Dividend ETFs With Higher Yields Than LQD

    July 24, 2012
    Once upon a time, the conventional wisdom was that investors should hold stocks as a source of long-term capital appreciation ...
  93. Is Pfizer Reversing?

    July 23, 2012
    New York, July 23rd ( - Shares of Pfizer, Inc. (NYSE:PFE) closed the trading day lower by $0.1 or -0.4% ...
  94. The Most Overbought Dow Stocks

    July 3, 2012
    Despite large first-quarter gains, two big Dow stocks show strong monthly chart formations and are worthy of new buying. ...
  95. Dow 30 Stocks With High Dividends

    June 1, 2012
    We combed through the Dow 30 to find some of its highest-yielding stocks.
  96. Wide Moat Research Vs. S&P 500

    May 11, 2012
    Comparing the performance of the Wide Moat strategy versus the S&P 500.
  97. Pfizer: Momentum Continues to Build

    May 3, 2012
    Pfizer: Momentum Continues to Build
  98. Exxon Mobil Staying Energetic

    May 2, 2012
    Exxon Mobil doesn't appear to be having any expansion problems whatsoever.
  99. The Costs Of Being Obese

    May 2, 2012
    Numbers released by the Mayo Clinic suggest obesity costs more than smoking.
  100. 5 Easy Ways to Cash In on US Dividends

    April 26, 2012
    If you’re outside the US looking in, there are important pros and cons to adding exchange traded funds from America to your ...
  • Showing 1-100 of 200 items
  • 1
  • 2
  • >>
Trading Center